

Ossian Health Economics and Communications

Bäumleingasse 20

4052

Basel

Switzerland

08 July 2020

To whom it may concern

Title of study: Cost-effectiveness of Lutetium [¹⁷⁷Lu] oxodotreotide versus everolimus in gastroenteropancreatic neuroendocrine tumors

Authors: Oscar Leeuwenkamp and Jayne Smith-Palmer

This letter is to confirm that I have read the above titled article and that in my opinion the statistical methods used are appropriate for the cost-effectiveness analysis presented.

Sincerely,

Dr William Valentine

Health Economics Director, Ossian Health Economics and Communications